Table 3.
First salvage chemotherapy regimens after failure of first-line cisplatin-based combination chemotherapy
| Regimen | Dose | Days | CR rate | N patients | References |
|---|---|---|---|---|---|
| TIP | |||||
|
Paclitaxel Ifosfamide Cisplatin |
175–200 mg/m2 1200 mg/m2 20 mg/m2 |
1 1–5 1–5 |
70% | 46 | Kondagunta [33] |
| VIP | |||||
|
Etoposide Ifosfamide Cisplatin |
75 mg/m2 1200 mg/m2 20 mg/m2 |
1–5 1–5 1–5 |
25% | 42 | Motzer [34] |
| VeIP | |||||
|
Vinblastine Ifosfamide Cisplatin |
0.11 mg/m2 1200 mg/m2 20 mg/m2 |
1 + 2 1–5 1–5 |
50% | 135 | Loehrer [35] |
| HD-CE Indiana | |||||
|
Carboplatin Etoposide PBSCT |
700 mg/m2 750 mg/m2 1 × 106 CD34 + /kg |
1–3 1–3 6 |
63% | 184 | Einhorn [38] |
| HD-CE MSKCC | |||||
|
Carboplatin %Etoposide PBSCT |
AUC8 400 mg/m2 2 × 106 CD34 + /kg |
1–3 1–3 5 |
55% | 48 | Kondagunta [39] |
CR complete remission, MSKCC Memorial Sloan Kettering Cancer Center, NR not reported, PBSCT autologous peripheral blood stem cell transplantation, PFS progression-free survival